Maridebart Cafraglutide
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses
Amgen · Phase 1 · Not yet recruiting · Enrollment 356
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Maridebart Cafraglutide: SC Presentation 1 | n/r | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide: SC Presentation 2 | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.